Sugi Predict

Sugi Predict / Compounds / SCHEMBL10320739

SCHEMBL10320739

SCHEMBL10320739

COc1ccc(C2(C)CCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 6/20 0.49
▸ SLC6A3 Q01959 5/20 0.49
▸ GRIN1 Q05586 1/20 0.49
▸ GRIN2A Q12879 1/20 0.49
▸ GRIN2B Q13224 1/20 0.49
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ OPRM1 P35372 1/20 0.47
▸ OPRL1 P41146 1/20 0.47
▸ MAOB P27338 2/20 0.46
▸ MAOA P21397 1/20 0.46
▸ BACE1 P56817 3/20 0.44
▸ ATM Q13315 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7862598 0.96 SLC6A4 (0.53) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL10639135 0.94 SLC6A4 (0.56) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL434091 0.91 CA1 (0.52) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL31525582 0.84 CYP3A4 (0.46) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL24351946 0.82 HTR3E (0.46) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL10319425 0.82 CYP3A4 (0.47) GRIN1GRIN2AGRIN2BCA12CA1
SCHEMBL21964289 0.82 MAOB (0.50) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL31525577 0.81 CYP3A4 (0.43) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL24342639 0.78 CA1 (0.48) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B
SCHEMBL14207854 0.78 HPGD (0.47) SLC6A4SLC6A3GRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025201504-A1 KAT6 INHIBITORS BEIGENE (SUZHOU) CO., LTD. (CN) 2025-10-02 — — WO disclosed
US-20250304535-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-10-02 — — US disclosed
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-10-26 — — US disclosed
EP-3523277-B1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS ABBVIE OVERSEAS SARL (LU) 2021-06-30 — — EP disclosed
EP-3523293-B1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS ABBVIE OVERSEAS SARL (LU) 2021-06-16 — — EP disclosed
US-20190315687-A1 Substituted Pyrrolidines and Methods of Use ABBVIE S.Á.R.L. (LU) 2019-10-17 — — US disclosed
US-10399940-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2019-09-03 — — US disclosed
EP-3523277-A1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS Abbvie S.a.r.l. (LU) 2019-08-14 — — EP disclosed
EP-3523293-A1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS Abbvie S.a.r.l. (LU) 2019-08-14 — — EP disclosed
US-9981910-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2018-05-29 — — US disclosed
US-20180099932-A1 Substituted Pyrrolidines and Methods of Use GALAPAGOS NV (BE) 2018-04-12 — — US disclosed
WO-2018065921-A1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS ABBVIE S.Á.R.L. (LU) 2018-04-12 — — WO disclosed
WO-2018065962-A1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS AbbVie S.à.r.l. (LU) 2018-04-12 — — WO disclosed
US-20180099931-A1 Substituted Pyrrolidines and Methods of Use ABBVIE S.Á.R.L. (LU) 2018-04-12 — — US disclosed
EP-2484661-B1 2,3-DIHYDRO-1H-INDENE-2-YLUREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME TORAY INDUSTRIES (JP) 2017-04-26 — — EP disclosed
US-8653304-B2 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same TORAY INDUSTRIES, INC. (JP) 2014-02-18 — — US disclosed
EP-2484661-A1 2,3-DIHYDRO-1H-INDENE-2-YLUREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME Toray Industries, Inc. (JP) 2012-08-08 — — EP disclosed
US-20120184735-A1 2,3-DIHYDRO-1H-INDENE-2-YL UREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME TORAY INDUSTRIES, INC. (JP) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304535-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT2A SLC6A4 1497/4885SLC6A3 1065/4885GRIN1 408/4885
US-20180099931-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 SLC6A4 3331/4885SLC6A3 2144/4885GRIN1 3937/4885
US-20190315687-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 SLC6A4 3250/4885SLC6A3 1911/4885GRIN1 3984/4885
US-10399940-B2 Substituted pyrrolidines and methods of use CFTR, PKD1, PKD2 SLC6A4 3250/4885SLC6A3 1911/4885GRIN1 3984/4885
US-20120184735-A1 2,3-DIHYDRO-1H-INDENE-2-YL UREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME SLC14A1, UROD, UGP2 SLC6A4 2222/4885SLC6A3 1028/4885GRIN1 4043/4885
US-20180099932-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 SLC6A4 3250/4885SLC6A3 1911/4885GRIN1 3984/4885
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF HRAS, KRAS, TP53 SLC6A4 4146/4885SLC6A3 4175/4885GRIN1 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.